New combo aims to halt early blood cancer before it worsens

NCT ID NCT03516617

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of two drugs, acalabrutinib and obinutuzumab, can eliminate signs of cancer in patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma who are at high risk of progression. About 120 participants will be randomly assigned to receive either acalabrutinib alone or both drugs together. The goal is to see if the combination leads to deeper remission and delays the need for further treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib and obinutuzumab
What this could lead to: If successful, this could offer a way to achieve deep remission in early-stage CLL/SLL, potentially delaying the need for more intensive treatment.
What could go wrong: This is a phase 2 trial with only 120 participants, so results are preliminary. The drugs may cause side effects like infections or bleeding, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States

Contact Email: •••••@•••••
Mayo Clinic in Florida
ACTIVE_NOT_RECRUITING

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.